Vitamin D Status in Patients with Systemic Lupus Erythematosus in Serbia: Correlation with Disease Activity and Clinical Manifestations
DOI:
https://doi.org/10.3889/oamjms.2015.052Keywords:
SLE, vitamin D, disease activity, glucocorticoids, vitamin D supplementsAbstract
BACKGROUND: Numerous studies indicate potential role of vitamin D as an important factor in the development of many autoimmune diseases including systemic lupus erythematosus (SLE). Patients with SLE are especially prone to the development of vitamin D deficiency due to the nature of their illness.
AIM: The aims of our study were to determine the prevalence of vitamin D insufficiency and deficiency in patients with SLE in Serbia, to identify clinical variables associated with vitamin D status and to examine the impact of vitamin D status on disease activity and presence of specific lupus autoantibodies.
MATERIAL AND METHODS: The study included 46 patients with SLE. Serum 25(OH)D concentration was measured by electrohemiluminiscent immunoassay.
RESULTS: The mean serum concentration of 25(OH)D was 11.9 ± 7.3 ng/ml. The prevalence of insufficiency was 32.6%, while the prevalence of deficiency was 67.4%. There was no association between vitamin D status and photosensitivity, skin lesions, arthritis and lupus nephritis. Vitamin D status was not associated with the presence of specific autoantibodies. There was no correlation between disease activity assessed by SLEDAI scale with the concentration of 25(OH)D. Patients who used vitamin D supplements and calcium did not have a significantly higher concentration of 25(OH)D.
CONCLUSION: In conclusion, vitamin D deficiency is common in patients with SLE.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357:266-281. DOI: https://doi.org/10.1056/NEJMra070553
Etten E, Mathieu C. Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005; 97:93-101. DOI: https://doi.org/10.1016/j.jsbmb.2005.06.002
Mora JR, Iwata M, Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nature Immunol. 2008; 8: 685-698. DOI: https://doi.org/10.1038/nri2378
Penna G, Adorinin L. 1,25-dihdroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000; 164:2405-2411. DOI: https://doi.org/10.4049/jimmunol.164.5.2405
Kamen D, Aranow C. Vitamin D in systemic lupus erythematosus. Curr Opin Rheum. 2008; 20:532-537. DOI: https://doi.org/10.1097/BOR.0b013e32830a991b
Lemire JM, Ince A, Takashima M: 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity. 1992; 12:143-148. DOI: https://doi.org/10.3109/08916939209150321
Barnes TC, Bucknall RC. Vitamin D deficiency in a patient with systemic lupus erythematosus. Rheumatology. 2004; 43:393-394.
Cutolo M, Otsa K. Vitamin D, immunity and lupus. Lupus. 2008; 17: 6-10. DOI: https://doi.org/10.1177/0961203307085879
Martins DC, Kang J, Kamen DL, et al. The treshold of vitamin D required for optimal immune regulation: implications for patients with lupus (abstract). Arthritis Rheum. 2006; 54:S431.
Orbach H, Zandman-Goddard G, Amital H, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci. 2007; 1109:385-400. DOI: https://doi.org/10.1196/annals.1398.044
Kamen DL, Cooper GS, Bouali H, Shaftma SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev. 2006; 5:114-117. DOI: https://doi.org/10.1016/j.autrev.2005.05.009
Bultinik IE, Lems WF, Kostense PJ et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005; 52:2044-2050. DOI: https://doi.org/10.1002/art.21110
Muller K, Kriegbaum NJ, Baslund B, et al. Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol. 1995; 14:397-400. DOI: https://doi.org/10.1007/BF02207671
Hiusman AM, White KP, Algra A, et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol. 2001; 28:2535-2539.
Szodoray P, Tarr R, Bazso A, Poor G, Szegedi G, Kiss E. The immunopathological role of vitamin D in patients with SLE: data from a single centre registry in Hungary. Scan J Rheumatol. 2011; 40(2):122-126. DOI: https://doi.org/10.3109/03009742.2010.507220
Damanhouri LH. Vitamin D deficiency in Saudi patients with systemic lupus erythematosus. Saudi Med J. 2009; 30(10): 1291-1295.
Bogaczewicz J, Sysa-Jedrzejowska A, Arkuszewska C, Zabek J, Kontny E, Wozniacka A. Prevalence of autoantibodies directed against 1,25(OH)2D3 in patients with systemic lupus erythematosus. Pol Merkur Lekarski. 2010; 28(164):103-107.
Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa, Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology. 2008; 47:920-923. DOI: https://doi.org/10.1093/rheumatology/ken121
Thudi A, Yin S, Wandstart AE, Li QZ, Olsen NJ. Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am J Med Sci. 2008; 335:99-104. DOI: https://doi.org/10.1097/MAJ.0b013e318134eeb6
Toloza SMA, Cole DEC, Gladman DD, Ibanez D, Urowitz MB. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010; 19:13-19. DOI: https://doi.org/10.1177/0961203309345775
Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007; 179:1634–1647. DOI: https://doi.org/10.4049/jimmunol.179.3.1634
O’Regan S, Chesney RW, Hamstra A, et al. Reduced serum 1, 25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand. 1979; 68:109–111. DOI: https://doi.org/10.1111/j.1651-2227.1979.tb04969.x
Barnes TC, Bucknall RC. Vitamin D deficiency in a patient with systemic lupus erythematosus. Rheumatology. 2004; 43:393-394. DOI: https://doi.org/10.1093/rheumatology/keh050
Sharma OP. Hypercalcemia in granulomatosus disorders: a clinical review. Curr Opin Pulm Med. 2000; 6:442-447. DOI: https://doi.org/10.1097/00063198-200009000-00010
Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990; 112: 352–364. DOI: https://doi.org/10.7326/0003-4819-112-5-352
Kimberg DV, Baerg RD, Gershon E, Graudusius RT. Effect of cortisone treatment on the active transport of calcium by the small intestine. J Clin Invest. 1971; 50:1309–1321. DOI: https://doi.org/10.1172/JCI106610
Chesney RW, Mazess RB, Hamstra AJ, DeLuca HF, O’Reagan S. Reduction of serum-1, 25-dihydroxyvitamin-D3 in children receiving glucocorticoids. Lancet. 1978; 2: 1123–1125. DOI: https://doi.org/10.1016/S0140-6736(78)92277-8
Bazso A, Tarr T, Szegedi G, Poor G, Kiss E. Immunomodulatory effects of vitamina D in Hungarian SLE patients. Bone. [abstract] 2009; S339-S450. DOI: https://doi.org/10.1016/j.bone.2009.03.176
Kim HA, Sung JM, Jeon JY, Yoon JM, Suh CH. Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus. Rheumatol Int. 2011;31(9):1189-94. DOI: https://doi.org/10.1007/s00296-010-1442-1
Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system. Arc Biochem Biophys. 2000; 374:334-338. DOI: https://doi.org/10.1006/abbi.1999.1605
Bhall AK, Amento EP, Serog B, Glimcher LH. 1,25-Dihydoxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol. 1984; 133:1748-1754.
Linker-Israeli M, Elstner E, Klinenberg JR, et al. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE derived PBMC. Clin Immunol. 2001; 99:82–93. DOI: https://doi.org/10.1006/clim.2000.4998
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
